Stave Therapeutics represents a significant milestone in New Zealand’s higher-education and biomedical research landscape. The new biotechnology venture, launched in mid-June 2026, stems directly from collaborative work between the University of Auckland and the Malaghan Institute of Medical Research. It translates years of academic immunology and drug-discovery research into a focused company targeting tumour-driven immune resistance in cancer.
University of Auckland and Malaghan Institute Combine Expertise for Clinical Impact
The venture brings together the Malaghan Institute’s deep expertise in immunology with the University of Auckland’s strengths in drug discovery at the Auckland Cancer Society Research Centre. Stave Therapeutics was established with support from Unruly Partners and UniServices, the University’s commercialisation arm. This partnership model exemplifies how New Zealand universities are increasingly bridging fundamental research and commercial application.
Initial focus centres on lung cancer, where immune checkpoint inhibitors provide benefit for some patients yet leave substantial unmet need. The company’s approach aims to re-activate the immune system inside tumours, where current treatments often fail. Broader applications across melanoma, breast, renal and liver cancers are anticipated given the widespread use of checkpoint inhibitors.
From Bench to Biotech: A Decade of Research Culminates in Spin-Out
Researchers at both institutions have worked on the underlying science for nearly a decade. The transition into Stave Therapeutics validates long-term investment in curiosity-driven research and demonstrates a clear pathway from laboratory discoveries to potential clinical trials. Professor Ian Hermans of the Malaghan Institute noted that the venture offers a tangible route to patients, underscoring the value of sustained public and philanthropic funding for New Zealand’s biomedical sector.
Photo by Austin Farrington on Unsplash
Commercialisation Model Strengthens New Zealand’s Research Ecosystem
UniServices’ involvement highlights the growing sophistication of university commercialisation offices in New Zealand. By partnering with specialist investors such as Unruly Partners, the University of Auckland is accelerating the translation of academic IP into investable companies. This approach aligns with national priorities to grow a knowledge-based economy and retain research talent domestically.
Stave Therapeutics is positioned as a first-in-class oncology company with strong intellectual property and a compelling development path. Early-stage funding and governance structures typical of such spin-outs provide a template for future ventures emerging from New Zealand universities.
Implications for Higher-Education Research Training and Careers
The launch creates new opportunities for PhD graduates and postdoctoral researchers in immunology, pharmacology and translational medicine. Spin-out companies often recruit directly from the institutions that generated the science, offering pathways that combine academic rigour with industry experience. New Zealand universities are increasingly viewed as incubators for high-value biotech talent, supporting both domestic retention and international attractiveness of the sector.
Broader Economic and Health-System Benefits
Lung cancer remains the leading cause of cancer death in New Zealand. Successful development of Stave’s platform could improve outcomes for thousands of patients while contributing to the growth of a domestic life-sciences industry. Successful clinical translation would also strengthen the case for continued government and philanthropic investment in university-based medical research.
Future Outlook and Next Steps
Stave Therapeutics enters a competitive global oncology landscape with a differentiated mechanism of action. The company’s clear route to clinical trials positions it for potential milestone achievements within the coming years. Continued collaboration between the founding institutions and the new venture will be critical to maintaining scientific momentum and ensuring that New Zealand retains a stake in the intellectual and economic returns.